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Abstract
This study progresses in the direction of identifying component(s) from the Mediterranean sponge, Spongia
officinalis with anticonvulsant and analgesic activities. We investigated the efficacy of crude extract and its
semi-purified fractions (F1-F3) of the defensive secretion from Spongia officinalis for their in vivo anticonvulsant
activity using the pentylenetetrazole (PTZ) seizure model and analgesic activity using the writhing test in mice.
Among the series the crude extract exhibited interesting analgesic activity in a dose dependent manner.
Similarly the fraction F2 showed a partial protection of mice from PTZ-induced seizure and interesting analgesic
activity in a dose dependent manner. The purification and the determination of chemical structure(s) of
compound(s) of this active fraction are under investigation.
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Introduction
The inability to cure contemporary disease such as cancer,
AIDS, arthritis, Alzheimer and the growing incidence of
drug-resistant infection diseases have stimulated the need
for the development of new drugs from natural sources.
Since the few last decades, marine environment have been
recognized to be a rich sources of bioactive metabolites
with varied biological and pharmacological activities [1,2].
Covering around 70% of the planet surface, the oceans pos-
sess a huge potential for the new discovery often on novel
molecules. The most interesting phyla with respect to
pharmacologically active marine compounds include bac-
teria, fungi, algae, soft corals and gorgonians, sea hares and
nudibranchs, bryozoans, tunicates and especially sponges
[3]. Marine sponges have been considered as a gold mine
during the past few decades with respect to the diversity of
their secondary metabolites and continue to provide novel
natural products with a remarkable chemical diversity. It is
not surprising that a sponge natural product possessed dif-
ferent pharmacological properties such as ceramide from
Negombata corticata [4] which displayed anticonvulsant
activitiy; manoalide, a sesterpenoid compound, from Luf-
fariella variabilis which displayed anti-inflammatory, anal-
gesic and antibacterial activities [5,6]. The objective of the
present study was to evaluate for the first time the potency
of crude extract and its semi-purified fractions (F1-F3) of
the defensive secretion from Spongia officinalis for inhibit-
ing convulsion induced by PTZ and for inhibiting writhes
induced by acetic acid and phenylbenzoquinone with the
aim of identifying novel molecules with interesting and po-
tentially useful pharmacological activities.
Materials and methods
Sample collection and preparation of the extract
The marine sponge, Spongia officinalis was collected from
the Mediterranean Sea, in various areas of the coastal re-
gion of Tunisia, at a depth between 2 and 3 meters. The
collected samples were cleaned by rising with sea water
and distilled water and transported in cool box to the la-
boratory where they are kept in a refrigerator in distilled
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water for 24 h. Identification of specimen was carried out
in the National Institute of Marine Sciences and Technolo-
gies, Salamboo, Tunisia.
The samples were defrosted before use and then filtered
using some cotton wool followed by passage through a
Whatman filter paper # 1. The filtrate was lyophilized to
give the crude extract of the defensive secretion. The pow-
dered extract was stored at −20°C until use.
Purification of the crude extract of the defensive secretion
Often, bioactive compounds constitute a very minor part
of the crude extract. In order to localize the active fraction,
extract of the defensive secretion of Spongia officinalis was
purified, using C18 cartridges (Sep-pack, Supelco), by gra-
dient elution with methanol–water mixture (0%, 25%, 50%
and 80% methanol) to give 4 fractions (F0-F3). Methanol
solvent was removed from fractions recuperated using ro-
tating evaporator at 35°C and distilled water was then
added to the residues and the aqueous phases were lyophi-
lized. The powdered fractions were stored at −20°C until
use.
Crude extract and fractions were diluted to the desired
final concentration immediately prior manipulation.
Animals
Swiss mice (20–30 g) of both sexes, provided from Pasteur
institute (Tunis, Tunisia) were used. Animals were fed a
standard diet ad libitum and allowed free access to drink-
ing water. Housing conditions and in vivo experiments
were approved according to the guidelines established by
the European Union on Animal care (CEE Council 86/
609).
Anticonvulsant study in mice
Anticonvulsant activity was assessed according to the
method described by Vogel [7]. Swiss mice of either
sex (20–30 g) were used. Animals were divided into
three groups of six mice each. Group one served as
control and was treated with 10 ml/kg of saline by
subcutaneous injection (s/c), the second group was
given phenobarbital (120 mg/kg) (s/c) as a reference
drug, and the third group was treated with the crude
extract of the defensive secretion from Spongia offici-
nalis (100, 200 and 400 mg/kg) and its semi purified
fractions (F1-F3) at 200 mg/kg (s/c), 30 min before
the intraperitoneal (i.p.) injection of pentylenetetrazole
(PTZ) (90 mg/ml). The time taken before the onset of
clonic convulsions, the duration of clonic convulsions,
and the percentage of seizure and mortality protection
were recorded. These parameters were compared in
treated animals with those of control animals, in
order to assess the anticonvulsant activity.
Nociceptive tests
Acetic acid writhing test in mice
The analgesic activity was performed according to the
method of Koster et al. [8]. Swiss mice (20–30 g) were
selected one day prior to each test and were divided into
three groups of six mice each. One group served as con-
trol (saline 10 ml/kg) (s/c). The second group was given
the lysine acetylsalicylate (ASL) (200 mg/kg) by the same
route, as a reference drug. The remaining group was
treated with the crude extract of the defensive secretion
from Spongia officinalis (100, 200 and 400 mg/kg) and
its semi purified fractions F1, F3 at 200 mg/kg and F2
(50, 100 and 200 mg/kg) (s/c). All animals received
10 ml/kg (i.p.) of 1% acetic acid 30 min after treatment.
The number of writhing was recorded during 30 min
commencing 5 min after the acetic acid injection. A
writhe is indicated by abdominal constriction and
stretching of at least one hind limb.
Phenylbenzoquinone (PBQ) writhing test in mice
Swiss mice (20–30 g) were used. In this test the same
procedure was used as described above, but writhing was
induced by i.p. injection of 10 ml/kg of 0.04% PBQ in a
5% ethanol aqueous solution [9]. Antinociceptive activity
was detected as a reduction in the number of abdominal
constrictions exhibited by treated mice, with standard
drug or with the sponge extract and its semi-purified
fractions, as compared to the nociception control group,
and was expressed as the percent of pain inhibition.
Acute toxicity study
Eighty mice were divided into eight groups of ten ani-
mals each. One group served as a control and received
0.9% NaCl alone (10 ml/kg) given intraperitoneally, while
the remaining seven groups were treated with increasing
doses of the crude extract of the defensive secretion from
Spongia officinalis; 300, 500, 700, 800 and 1000 mg/kg (i.
p.), respectively. The mortality rate within a 24 h period
was determined and the LD50 was estimated according
to the method described by Miller and Trainter [10].
According to the results of acute toxicity test, the doses
of 100, 200 and 400 mg/kg were chosen for experiments.
Statistical analysis
Data are presented as the mean± standard error (s.e.m).
Statistical analysis was performed using Student’s t-test.
The significance of difference was considered to include
values of P< 0.05.
Results and discussion
Epilepsy is one of the most common serious neurological
conditions. Seizures have traditionally been recognized as
a symptom of abnormal neuronal synchronization, and
until recently have been thought to be a result of aberrant
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synaptic communication [11]. The insufficient efficacy of
modern anticonvulsive drugs used in clinical practice, as
well as wide global distribution of epilepsy, makes the de-
sign of novel compounds very important [12]. Convulsive
seizures induced by administration of blocker of γ-amino-
butyric acid (GABA) receptor Cl- channels PTZ (90 mg/
kg) (i.p.) were used as experimental epilepsy model. The
forbrain is involved in the expression of clonic seizures,
whereas the activation of brainstem structures participates
in the expression of the tonic component [13]. Single dose,
intraperitoneal administration of PTZ (90 mg/kg) caused
clonic convulsions as well as lethality in mice. The pre-
treatment of mice with Phenobarbital (120 mg/kg) com-
pletely prevented all manifestations of convulsive attacks
(Table 1). Pretreatment of the mice with the crude extract
of the defensive secretion of Spongia officinalis caused a
partial protection against PTZ-induced convulsions as
shown in Table 1. The dose of 400 mg/kg had no signifi-
cant effect on number of deaths. However, it prolonged
the onset of clonic convulsions from 180 to 600 seconds
and decreased the duration of seizure (Table 1). After s/c
administration of the three semi-purified fractions (F1-F3)
obtained by fractionation of the crude extract of the defen-
sive secretion, protection against PTZ-induced convulsions
was revealed with fraction F2 in a dose-dependant manner.
At the dose of 100 mg/kg, F2 significantly increased the la-
tency of seizure and decreased the duration of seizure
compared to control. The next higher dose (200 mg/kg)
had similar effects; moreover it caused 30% protection
against PTZ-induced lethality in mice (Table 1). The pro-
longed onset time of PTZ-induced convulsions suggested
an inhibitory action of the central nervous system [14].
Table 1 Anticonvulsant effect of the subcutaneous administration of crude extract and its semi-purified fractions (F1-F3)
of the defensive secretion of Spongia officinalis in the PTZ model in mice
Treatment Dose (mg/kg) Onset of first clonus (s) Duration (s) Seizure protection (%) Mortality protection (%)
Control(saline 10 ml/kg) - 180.16 ± 53.66 15 ± 1.16 0 0
Crude extract 100 149 ± 35.77ns 12 ± 87.24ns 0 0
200 251 ± 17.88 ns 10.7 ± 3.57ns 0 0
400 600 ± 0** 5 ± 2.68** 30 0
F1 200 251 ± 9.83* 18 ± 3.57ns 0 o
F2 50 247 ± 17.88 ns 8.7 ± 1.97** 0 0
100 800 ± 17.88** 4 ± 0.71** 20 0
200 1200 ± 89.44** 1 ± 0.89** 50 30
F3 200 249 ± 10.73 ns 13 ± 1.07ns 0 0
Phenobarbital (reference drug) 120 - - 100 100
Values are expressed as mean± s.e.m. *P< 0.01, **P< 0.001, ns: not significant. n = 6 animals.
Table 2 Analgesic effect of the subcutaneous
administration of crude extract and its semi-purified
fractions (F1-F3) of the defensive secretion of Spongia







Control (saline 10 ml/kg) - 82.33 ± 12.45 -
Crude extract 100 41.83 ± 12.52** 49.19
200 39± 5.76** 52.63
400 31± 3.46** 62.34
F1 200 34± 3.79** 58.7
F2 50 24± 2.09** 70.85
100 18.5 ± 5.43** 77.53
200 12 ± 4** 85.42
F3 200 37± 3.88** 54.65
Lysine Acetylsalicylate
(reference drug)
200 26.16 ± 8.37** 68.21
Values are expressed as mean± s.e.m. **P< 0.001. n = 6 animals.
Table 3 Analgesic effect of the subcutaneous
administration of crude extract and its semi-purified
fractions (F1-F3) of the defensive secretion of Spongia







Control (saline 10 ml/kg) - 39 ± 2.6 -
Crude extract 100 14.33 ± 5.16** 63.24
200 12.33 ± 4.8** 68.37
400 9.66 ± 5.08** 75.21
F1 200 12± 3.74** 69.23
F2 50 11± 4.19** 71.79
100 8 ± 3.4** 79.48
200 7 ± 2.36** 82.05
F3 200 11.33 ± 4.32** 70.94
Acetylsalicylate of lysine
(reference drug)
200 10 ± 2.6** 74.35
Values are expressed as mean± s.e.m. **P< 0.001. n = 6 animals.
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The majority of currently available antiepileptic drugs
(AEDs) fall into one of two pharmacological classes, those
that modulate neuronal voltage-gated sodium channels
and those that modulate inhibitory GABAergic neuro-
transmission. While, small number of AEDs may exert
their effects via an interaction with voltage-operated cal-
cium channels [15].
Most antiepileptic drugs are known to have strong an-
algesic effects [16]. Moreover the available analgesic
drugs exert a wide range of side effects and are either
too potent or too weak; the search for new analgesic
compounds has been a priority of pharmacologists and
pharmaceutical industries [17].
Among the several models of visceral pain, writhing test
has been mostly used as a standard screening method [18].
In this study, results of the writhing tests are shown in
Tables 2 and 3. The mouse writhing model involves differ-
ent nociceptive mechanisms, such as the sympathetic sys-
tem (Biogenic amines release), cyclooxygenases (COX)
and their metabolites [19] and opioid mechanisms [20].
Acetic acid acts indirectly by inducing the release of en-
dogenous mediator, which stimulates the nociceptive neu-
rons sensitive to NSAIDs (non-steroidal anti-inflammatory
drugs) and/or opioids [20]. The PBQ-induced writhing re-
sponse is believed to be produced by the liberation of en-
dogenous substance(s), notably metabolites of the
arachidonic cascade [20]. However, the PBQ test is not
specific for weak analgesics such as the NSAIDs, as it also
detects centrally active analgesics [9,21]. The subcutaneous
administration of the crude extract of Spongia officinalis
(100, 200 and 400 mg/kg) produced a significant reduction
in the number of abdominal constrictions throughout the
entire period of observation in a dose related manner with
respectively 49.19, 52.63 and 62.34% in the acetic acid
writhing test (Table 2) and 63.24, 68.37 and 75.21% in the
PBQ writhing test in mice (Table 3). Within the series
studied, significant activity was observed with F2 (50, 100
and 200 mg/kg) in a dose related manner, with respectively
70.85, 77.53 and 85.42% in the acetic acid writhing test
(Table 2) and 71.79, 79.48 and 82.05% in the PBQ writhing
test in mice (Table 3), whereas at the same time, fractions
F1 and F3 (200 mg/kg) inhibited writhing by 58.7 and
54.65% in the acetic acid writhing test and 69.23 and
70.94% in the PBQ writhing test in mice, respectively
(Tables 2,3). Standard drug (ASL, 200 mg/kg) decreased
the number of abdominal constrictions by 68.21% in the
acetic acid writhing test and 74.35% in the PBQ writhing
test in mice, respectively (Tables 2,3). We have demon-
strated, using conventional pharmacological model, the
analgesic property of the crude extract of the defensive se-
cretion and its semi-purified fractions. The crude extract
of the defensive secretion and its semi-purified fractions
can induce antinociception by mechanism similar to non-
narcotics and or narcotic drugs, perhaps by blocking the
receptor or the release of endogenous substances that ex-
cite pain nerve endings [22]. NSAIDs such ASL produce
their antinociceptive and anti-inflammatory action via
inhibiting cyclooxygenases in peripheral tissues, thereby
reducing PGE2 (prostaglandin E2) synthesis and interfer-
ing with the mechanism of transduction in primary affer-
ent nociceptors [23]. This particular activity of the crude
extract of the defensive secretion and its semi-purified
fractions is probably related to their anti-inflammatory
properties [24].
Evaluating anticonvulsant and analgesic properties in a
single assay may not provide a full understanding of the
actions of fraction or its utility. Further work to establish
the active chemical constituent(s) of the active fraction
F2 and ascertain its mechanism of action is currently
going on in our laboratory.
Some known anticonvulsant and analgesic agents, such
as ceramide [4], manoalide [25], disideine [26] and avarol
[27] have already been isolated from other sponges.
However, marine sponges often contain diverse and
abundant microbial communities, including bacteria
which are the most dominant group of microbial associ-
ation in sponges, archaea, microalgae and fungi. In some
cases, these microbial associates comprise as much as
40% of the sponge volume and can contribute signifi-
cantly to host metabolism [28,29]. These data allows us
to suggest that, in our case, the exact origin of the anti-
convulsant and the analgesic properties remains un-
known or from the active fraction of Spongia officinalis
or from the symbiotic microorganisms. Isolation and cul-
tivation of suspected symbiotic bacteria either from the
surrounding sea-water or from the sponge could provide
a better answer.
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